Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that its wholly-owned subsidiary KGK Science Inc has completed an open label study, in which Gefion Canada GT4 technology was used to successfully deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin.
The mental healthcare company said Gefion GT4 technology, which uses novel penetrating agents to transport CBD and THC through the skin and directly into the blood, may provide lower, more steady-state cannabinoid concentrations that minimize psychoactive effects in participants.
“This study represents an important step forward in cannabis research,” KGK Science scientific director Erin Lewis said in a statement.
READ: Wellbeing Digital Sciences inks deal to sell its IRP Health subsidiary to Pathway Health
“This study opens the door for future double-blind, placebo-controlled trials to further investigate topical cannabis delivery,” Lewis added.
Wellbeing noted that the findings present a potential benefit in the treatment of chronic conditions over longer periods of time, or in the treatment of diseases where high concentrations of cannabinoids are needed in relation to the body weight of vulnerable populations such as pediatrics.
It added that CBD and THC delivery in the study was found to be safe and well tolerated by all participants, with none of the volunteers experiencing any intoxicating effects.
Topical cannabis may provide the benefit of extended cannabinoid delivery without the worry of intoxication, suggesting it may be beneficial for certain lifestyles and therapeutic indications, but more research is needed, according to the company.
Wellbeing Digital is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research.
A subsidiary of Wellbeing Digital, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging healthcare products.
Contact Sean at sean@proactiveinvestors.com